Participated · Series A · Apr 2026

Sonire Therapeutics develops a next-generation HIFU therapy system that combines real-time imaging guidance with patented technologies such as a noise-cancellation system, cavitation bubble visualization, a robot-assisted positioning platform and rapid multi-focus scanning. The system is designed to provide precise thermal ablation of tumors in an anesthesia-free, outpatient procedure that can be performed in approximately 20 minutes by a single physician. Sonire positions its therapy as a complement to chemotherapy to potentially prolong overall survival while offering a less invasive alternative to surgery or radiation. Foundational academic work with a prototype (MoonShot-2) demonstrated a 66% disease control rate in advanced or refractory pancreatic and biliary tract cancers and informed the current system. The SUNRISE-I randomized trial (HIFU with chemotherapy vs. chemotherapy alone) is ongoing across seven leading Japanese hospitals. The company holds 25 issued patents and 22 pending, was founded in February 2020 in Tokyo, and is now headquartered in Palo Alto, California; it recently raised $18 million in a Series A to advance clinical, regulatory, and commercialization efforts.

Led · Equity · Nov 2023

ThinkCyte develops VisionSort, the company’s flagship AI-based, dual-mode fluorescence and morphometric cell sorting platform, launched in June 2023. VisionSort has been adopted by major biopharmaceutical companies and leading academic research institutions worldwide. The company plans to use new funding to scale production and manufacturing and to accelerate global commercial expansion of VisionSort. ThinkCyte completed a Series C financing (including a recent extension) and also secured a loan to support growth. The new proceeds bring ThinkCyte’s total funding to $91 million. ThinkCyte was founded in 2016 and maintains offices in Tokyo, Japan and Redwood City, California. ThinkCyte develops scientific instruments that combine proprietary optics, microfluidics, and artificial intelligence to enable high‑throughput, label‑free single‑cell analysis and sorting using its Ghost Cytometry technology. Its flagship product, VisionSort, commercially launched in June and is an AI‑based dual‑mode fluorescence and morphometric cell sorting platform. Since the summer launch the company has completed deliveries to major pharmaceutical companies and leading research institutions in the U.S. The company plans to use new funding to expand production capacity for VisionSort and accelerate sales across North America, Europe, and Asia. ThinkCyte says it will continue developing complementary technologies and products to broaden the impact of Ghost Cytometry in life sciences. The company was founded in 2016 and has offices in Tokyo and Redwood City, California. ThinkCyte develops life‑science research, diagnostic, and therapeutic platforms built around its proprietary image‑based high‑throughput cell sorting technology, Ghost Cytometry. The company focuses on drug discovery, cell therapy, and clinical diagnostics applications of its image‑based cell analysis and sorting system. ThinkCyte intends to use new funding to accelerate development of its cell‑therapy sorting system, expand clinical diagnostics and drug‑discovery activities, and pursue global business growth. The company was founded in 2016 and is led by CEO Waichiro Katsuda. ThinkCyte is based in Tokyo, Japan, and also maintains offices in San Carlos, California. The recent financing strengthens its balance sheet to support product development and international expansion plans.

Participated · Series D · Jul 2022

AnyMind offers a suite of products for brands and online operators, including conversational commerce AnyChat, e-commerce management AnyX, manufacturing AnyFactory and logistics AnyLogi. The company integrates with marketplaces such as Shopee, Rakuten, Lazada, Amazon and Shopify and supports more than 1,000 brands, 1,110+ publishers and 1,400+ creators. AnyMind operates 17 offices across 13 markets with over 1,000 employees and reports $174 million in revenue. It grew through aggressive acquisitions (POKKT, Moindy, Acqua Media, LYFT and ENGAWA) and has retained many acquired founders in leadership roles. Management says it plans to use the latest funding to make additional acquisitions in Japan and globally. AnyMind began as an internet advertising business (formerly AdAsia) and has expanded into HR and broader marketing services, plus a new creators network. The company is moving into outdoor advertising in Thailand via a joint venture with VGI and has acquired Thai YouTube media company Moindy. It recently launched CastingAsia Creators Network to complement its marketing and media units. AnyMind says it has been profitable since early 2017; reported 2017 revenue was $26M (up from $12.9M the prior year) and the CEO expected revenue for the current year to be more than double 2017. The business operates across 11 Asian markets, with 12 offices (including a product development center in Vietnam), about 330 staff and more than 1,000 clients across three businesses. The company also maintains a sizeable office in Bangkok as it pursues regional expansion. AnyMind Group is a Singapore-based holding group (formed this year) that applies AI across online advertising, marketing, influencer and HR products, including AdAsia, TalentMind and CastingAsia. AdAsia offers ad solutions to publishers and advertisers, TalentMind focuses on HR, and CastingAsia handles influencer marketing. The company has been profitable since early 2017 and reported $26 million in revenue for 2017, up from $12.9 million in 2016, and expected 2018 revenue to be more than double 2017. AnyMind operates in 11 Asian markets with 12 offices (including a product development center in Vietnam), roughly 330 staff and serves over 1,000 clients; Southeast Asia supplies the majority of revenue while its one-year Japan operation accounts for about 30 percent. The company plans to expand market share across Asia, pursue strategic acquisitions, enter new markets such as India and the Middle East next year, and build additional software based on its AI technology. Leadership has indicated an intention to pursue an IPO around 2020, with potential destinations including Tokyo, New York or Hong Kong.